Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ERZ4 | ISIN: US2528281080 | Ticker-Symbol: 87E
Tradegate
06.06.25 | 16:00
17,000 Euro
+2,41 % +0,400
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DIANTHUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DIANTHUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
16,40016,70006.06.
16,40016,60006.06.

Aktuelle News zur DIANTHUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.05.Dianthus Therapeutics appoints new board member1
DIANTHUS THERAPEUTICS Aktie jetzt für 0€ handeln
22.05.Dianthus Therapeutics, Inc.: Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors1
22.05.Dianthus Therapeutics, Inc. /DE/ - 8-K, Current Report2
13.05.Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views1
12.05.Dianthus Therapeutics GAAP EPS of -$0.82 beats by $0.03, revenue of $1.16M beats by $0.35M3
12.05.Dianthus Therapeutics, Inc. /DE/ - 8-K, Current Report2
12.05.Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results74Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103...
► Artikel lesen
05.05.Dianthus Therapeutics schließt Patientenrekrutierung für MaGic-Studie ab1
05.05.Dianthus Therapeutics completes enrollment for MaGic trial1
05.05.Dianthus Therapeutics, Inc.: Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September108MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103...
► Artikel lesen
29.04.Dianthus Therapeutics, Inc.: Dianthus Therapeutics to Participate in Two Upcoming Investor Events1
12.03.Stifel maintains Buy rating on Dianthus Therapeutics stock1
11.03.Dianthus Therapeutics GAAP EPS of -$0.81 beats by $0.04, revenue of $1.33M beats by $0.47M2
11.03.Dianthus Therapeutics, Inc. /DE/ - S-8, Securities to be offered to employees in employee benefit plans1
11.03.Dianthus Therapeutics, Inc. /DE/ - 10-K, Annual Report3
11.03.Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results160Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy...
► Artikel lesen
05.03.Dianthus Therapeutics appoints John King as CCO2
05.03.Dianthus Therapeutics, Inc.: Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors4
05.03.Dianthus Therapeutics, Inc. /DE/ - 8-K, Current Report-
18.02.Dianthus serviced residences at Tropicana Gardens PJ receives GBI Silver certification1
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1